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Using a functional model of breast cancer heterogeneity, we previously showed that 
clonal sub-populations proficient at generating circulating tumour cells were not all 
equally capable of forming metastases at secondary sites
1
. A combination of 
differential expression and focused in vitro and in vivo RNAi screens revealed 
candidate drivers of metastasis that discriminated metastatic clones. Among these, 
Asparagine Synthetase (ASNS) expression in a patient’s primary tumour was most 
strongly correlated with later metastatic relapse. Here, we have shown that 
asparagine bioavailability strongly influences metastatic potential.  Limiting 
asparagine by Asns knockdown, treatment with L-asparaginase, or dietary 
asparagine restriction reduced metastasis without impacting growth of the primary 
tumour, whereas increased dietary asparagine or enforced Asns expression 
promoted metastatic progression. Altering asparagine availability in vitro strongly 
influenced invasive potential, and this was correlated with an impact on proteins 
that promote the epithelial to mesenchymal transition. This provides at least one 
potential mechanism for how the bioavailability of a single amino acid could 
regulate metastatic progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
The majority of women with breast cancer do not succumb to their primary tumour but 
instead to metastases that become apparent after the primary lesion has been removed. In 
order for cells to contribute to metastases, they must leave the primary site, enter the 
vasculature, survive in the blood and then extravasate and colonize secondary sites. Our 
prior studies of a murine model of breast tumour heterogeneity, identified two clonal 4T1 
sub-lines with a strong propensity to form circulating tumour cells (CTCs) through a non-
invasive mechanism requiring vascular mimicry (4T1-E and –T)1,2. These two clones 
differed in their ability to form metastases, with 4T1-T preferentially colonizing brain, 
liver, and lungs. The distinction between the metastatic potential of the two CTC forming 
clones offered the opportunity to identify drivers of metastasis, which exert their effects 
late in metastatic progression. 
 
To validate the observation that 4T1-T had greater metastatic potential among CTC-
proficient clones, we combined equal numbers of 4T1-E and –T cells and introduced 
these directly into the bloodstream of immune compromised recipients (NOD-SCID-
Il2rg
−/−
 (NSG) mice). Though the two clones were initially present in equal abundance 
(Fig. 1a), when cells were harvested from the lung at day 7, clone T predominated, with 
its relative representation being inversely correlated with the total number of cells 
injected.  
 
We identified 192 genes with higher expression in 4T1-T than 4T1-E cells 
(Supplementary Table 1). Their corresponding Gene Ontology terms were enriched for 
processes important for metastatic spread (Supplementary Table 2, e.g. cell migration and 
locomotion). A retrospective analysis of patient data showed that genes within the set are 
more highly expressed in aggressive breast tumour subtypes (Extended Data Fig. 1a)
3
. 
They were also more highly expressed in the primary tumours of patients with later 
relapse to the bone, brain, and lungs as compared to primary tumours of relapse-free 
survivors (Extended Data Fig. 1b for lung).  
 
To identify metastatic drivers, we carried out an RNAi screen, with two arms (Fig. 1b). In 
total, 26 pools of approximately 40 short hairpin RNAs (shRNAs) targeting protein 
coding members of the 192 gene set, were introduced into 4T1-T cells.  
4
. These were placed onto matrigel or introduced into NSG mice by tail vein injection. 
After 24 hours, the cells that had invaded through matrigel were collected and, after 7 
days, lungs were harvested from the mice. Using high-throughput sequencing, we 
identified shRNAs that were depleted from the invaded cell populations or lung 
metastases, presumably because they targeted genes important for these processes. Strong 
overlap was observed when the in vitro and in vivo candidates were compared (Fig. 1c, 
Supplementary Table 3). 
 
Of the 11 candidate genes that scored in both the in vitro and in vivo assays, Asparagine 
Synthetase (Asns) had the most robust clinical evidence supporting its relevance to 
disease progression (Extended Data Fig. 1c). Expression levels of the human orthologue, 
ASNS, were predictive of general and lung-specific relapse in two breast cancer patient 
datasets. Also, when a small collection of matched tumour and lung metastases were 
transcriptionally profiled, ASNS was found to be more highly expressed in secondary 
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lesions. ASNS is more highly expressed in aggressive tumour subtypes (Extended Data 
Fig. 1d) and it is more highly expressed in patients with relapse to the lymph node, brain, 
liver, and lungs as compared to relapse-free survivors (Extended Data Fig. 1e). 
Subsequent analyses identified ASNS as predictive of survival in three additional breast 
cancer patient datasets (Extended Data Fig. 1f). In addition to breast, ASNS is negatively 
correlated with survival in 4 out of the 10 other solid tumours in the TCGA Pan-Cancer 
dataset (Extended Data Fig. 1g) and is a globally predictive biomarker for solid tumours 
(Extended Data Fig. 1h). Previous research has shown that asparagine is an important 
regulator of cellular metabolism and adaptation
5,6
.  
 
To validate Asns as a metastatic driver, we infected 4T1-T cells with two shRNAs 
targeting Asns or a control and introduced these cells intravenously into NSG mice 
(Supplementary Table 4). Asns-silenced cells produced significantly fewer lung 
metastases (Fig. 2a and Extended Data Fig. 2a). Asns-silenced cells also showed poor 
invasion into matrigel (Fig. 2b and Extended Data Fig. 2b). Silencing Asns did impact 
proliferation in vitro; however, this defect was minor compared to that observed in the 
invasion assay (Extended Data Fig. 2c, d). Intracellular free asparagine was reduced by 
silencing of Asns in 4T1-T cells (Extended Data Fig. 2e), and the abilities to invade and 
proliferate were increased in Asns-silenced cells when media was supplemented with 
asparagine (Extended Data Fig. 2f, g). 
 
When Asns-silenced cells were injected into the mammary fat pad, no significant change 
in primary tumour formation was observed (Fig. 2c), yet CTCs and lung metastases were 
reduced (Fig. 2d, e). Although statistically insignificant, metastases initiated by silenced 
cells were noticeably smaller, hinting at a growth defect at the metastatic site (Fig. 2f). 
Similar results were obtained with Asns-silenced parental 4T1 cells, indicating that Asns 
dependency is not a peculiarity of a single clonal line (Extended Data Fig. 3a, b). 
Enforced Asns expression in parental 4T1 populations did not affect primary tumour 
growth but did increase metastases both in number and size (Extended Data Fig. 3c-e). 
Similar outcomes were observed upon enforced ASNS expression in human MDA-MB-
231 breast cancer cells (Extended Data Fig. 3f-i). 
 
To determine whether the observed effects were unique to asparagine, we supplemented 
media separately with other non-essential amino acids lacking in the culture media, or 
with glycine, which is present and acted as a negative control, and assayed cells for 
invasiveness. 4T1 cells responded uniquely to asparagine supplementation, with an 
approximately 2-fold increase in invasiveness (Fig. 3a), though levels of uptake were 
similar for each of the amino acids with the exception of aspartic and glutamic acid 
(Extended Data Fig. 4a). More profound impacts were observed with MDA-MB-231 
cells (Extended Data Fig. 4b, c). Growth was not affected by asparagine supplementation 
for either cell line during the same period. (Extended Data Fig. 4d, e).   
 
Since invasiveness could be modulated either by altering asparagine biosynthetic capacity 
or by modifying extracellular pools, we asked whether metastasis could be influenced by 
treatment with L-asparaginase. This enzyme is used to treat acute lymphoblastic 
leukaemia (ALL), which is generally highly dependent on extracellular asparagine
7,8
. L-
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asparaginase has proven ineffective for treating solid tumours, in accord with Asns 
silencing not impacting growth at the primary site
9
. NSG mice harbouring orthotopic 4T1 
tumours were treated with 60 U L-asparaginase 5 times per week for 19 days, reducing 
serum asparagine to undetectable levels (Supplementary Table 5). While no significant 
difference, compared to controls, was detected in primary tumours, a reduction in 
metastasis was observed (Extended Data Fig. 5a-c). 
 
In TEL-AML1 negative ALL patients, resistance to L-asparaginase is thought to be 
achieved through increased biosynthetic production of asparagine
10
. When Asns-silenced 
cells were injected orthotopically into L-asparaginase treated mice, metastases were 
nearly undetectable (Fig. 3b and Extended Data Fig. 5d). In this case, a reduction of 
primary tumour volume was also observed (Extended Data Fig. 5e). Similar results were 
obtained with ASNS-silenced MDA-MB-231 cells (Extended Data Fig. 5f, g). 
 
The availability of extracellular asparagine can also be manipulated by altering 
asparagine levels in the diet. shRNA-infected 4T1-T cells were orthotopically injected 
into mice that received either a control, low-asparagine, or high-asparagine chow (0.6%, 
0%, and 4%, respectively). HPLC confirmed that serum asparagine levels were 
significantly altered in concordance with dietary intake (Extended Data Fig. 6a). 
Asparagine restriction did not impact primary tumour growth, regardless of Asns-
expression status (Extended Data Fig. 6b). In contrast, metastatic burden was decreased 
in animals that were fed low-asparagine diets and increased in animals given high-
asparagine diets (Fig. 3c and Extended Data 6c). Metastases were nearly undetectable in 
mice that were injected with Asns-silenced cells and fed a low-asparagine diet. Similar 
results were obtained when parental 4T1 cells were orthotopically injected into animals 
fed these same asparagine-controlled diets (Extended Data Fig. 6d-f).  
 
Analyses of the mammary gland, serum, and lungs of mice by mass spectrometry suggest 
that, under normal physiological conditions, asparagine levels are highest in mammary 
gland and lowest in serum (Fig. 3d). High asparagine availability in the mammary gland 
might blunt the impact of Asns silencing or changes in global asparagine levels on 
primary tumour growth, while low levels in the serum may make CTCs susceptible to 
these manipulations. Overall, asparagine abundance in tissues correlated with Asns 
expression (Extended Data Fig. 6g). ASNS expression levels follow a similar pattern 
across human tissues (Extended Data Fig. 6h), raising the possibility of similar impacts if 
asparagine levels were altered in patients
11
. 
 
To understand the mechanism by which asparagine availability might impact invasion 
and metastasis, we examined expression changes induced by Asns silencing, both at the 
RNA and protein level. RNA measurements were the strongest predictor of protein-level 
changes (Extended Data Fig. 7a). In accord with a previous report of translational 
pausing at asparagine residues in L-asparaginase treated cells, we also found asparagine 
content to be predictive of corresponding protein-level changes (Extended Data Fig. 
7a)
12
, irrespective of whether they were normalized for RNA levels (Extended Data Fig. 
7b).  
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Amongst the asparagine-enriched proteins that were depleted upon Asns silencing, we 
found genes whose human orthologues were up-regulated after induction of the 
epithelial-to-mesenchymal transition (EMT) (Fig. 4a and Extended Data Fig. 7c, 
Supplementary Table 6, EMT-up proteins)
13
. Overall, depleted proteins had 10% higher 
asparagine content than the analysed proteome as a whole, while EMT-up proteins had 
19% higher asparagine content (Extended Data Fig. 7c). Human EMT-up proteins are 
also asparagine-enriched (Extended Data Fig. 7c). A reanalysis of existing ribosomal 
profiling data revealed high rates of pausing at asparagine residues within EMT-up genes 
in L-asparaginase treated human prostate cancer cells (Extended Data Fig. 7d, e), and 
these same proteins increased in expression when parental 4T1 cells were cultured in 
elevated asparagine (Fig. 4b)
12
. Asparagine enrichment is a globally conserved property 
of EMT-up proteins, with enrichment being greatest in mammals (Extended Data Fig. 8).   
 
EMT-up genes were also down-regulated at the transcriptional level in Asns-silenced 
cells (Extended Data Fig. 9a). EMT-up genes were also increased in their mRNA levels 
when parental 4T1 cells were grown in asparagine supplemented media (Extended Data 
Fig. 9b). A reanalysis of existing data also showed reduced expression of EMT-up genes 
when ATF4, which regulates ASNS transcription, was deleted in haploid cells (Extended 
Data Fig. 9c), and liver cells from L-asparaginase treated ATF4 knockout mice were 
more perturbed in their EMT program than were similarly treated WT mice (Extended 
Data Fig. 9d)
14,15
. Considered together, these data suggested that asparagine 
bioavailability might impact metastasis, at least in part, through regulation of EMT. 
 
To examine the role of EMT in metastasis in our model, we orthotopically injected 4T1-T 
cells in which we had silenced expression of Tgf-ß, a key driver of EMT (Supplementary 
Table 4)
16
. Primary tumour growth was unaffected by this manipulation (Extended Data 
Fig. 9e); however the expression of two prototypical EMT markers (Twist1 and E-
cadherin) were altered to indicate a perturbed EMT program (Extended Data Fig. 9f, g). 
Tgf-ß-silenced cells produced fewer metastases from the primary tumour or when 
intravenously injected (Extended Data Fig. 9h, i). 
 
Although no differences were detected in H&E stained tumour sections, morphological 
distinctions were noticeable when shRNA infected 4T1-T cells were isolated from 
primary tumours by 6-TG selection, with most Asns-silenced cells displaying an 
epithelial morphology (Extended Data Fig. 10a, b). The majority of 6-TG isolated 
metastatic cells displayed a mesenchymal morphology, regardless of Asns-expression 
status, and this was matched by an increase in the expression of EMT-up genes (Fig. 4c). 
Nevertheless, EMT-up genes were down-regulated in Asns-silenced vs. –expressing 
metastatic cells, indicating an increased representation of epithelial cells in the silenced 
populations. Similarly, EMT-down genes were up-regulated, and Twist and E-cadherin 
expression measurements indicated a higher epithelial representation in Asns-silenced 
primary tumour cell populations (Fig. 4d). These results were validated by qPCR for 
Twist and E-cadherin in Asns-silenced and –expressing cells that were FACS isolated 
from primary and secondary lesions (Extended Data Fig. 10c, d). 
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Staining for Twist and E-cadherin proteins confirmed that EMT is perturbed in Asns-
silenced tumours, and this same pattern was observed in the corresponding metastases 
(Fig. 4e and Extended Data Fig. 11a-c). Similar patterns were observed in the primary 
tumours of mice that had been treated with L-asparaginase (Extended Data Fig. 11d, e) or 
subjected to dietary asparagine restriction (Extended Data Fig. 11f, g). 
 
Our model of breast tumour heterogeneity has strongly implicated asparagine 
bioavailability as a regulator of metastatic progression. This is also likely relevant in 
human cancers, as high ASNS expression is a marker of poor prognosis for many tumour 
types. One mechanism underlying our findings is likely a link between asparagine 
bioavailability and EMT, which can be observed in vitro and in vivo. In our breast cancer 
model, the gating step probably occurs in the circulation, where asparagine levels are low 
and are strongly affected by either L-asparaginase treatment or dietary restriction. 
Nonetheless, we do see effects on ratios of epithelial- to mesenchymal-like tumour cells 
at the primary and secondary site, which could also impact both tumour progression and 
response to therapy.   
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Cell culture 
The mouse mammary tumour cell line 4T1 (ATCC) and any derived clonal cell line were 
cultured in DMEM high glucose supplemented with 5% fetal bovine serum, 5% fetal calf 
serum, MEM non-essential amino acids (NEAA) and penicillin-streptomycin (Thermo 
Fisher Scientific). The human breast tumour cell line MDA-MB-231 (ATCC) was 
cultured in DMEM high glucose supplemented with 10% fetal bovine serum, NEAA and 
penicillin streptomycin (Thermo Fisher Scientific). The 4T1 and MDA-MB-231 cell lines 
were tested and authenticated by ATCC. The Platinum-A (Cell BioLabs) and 293FT 
(Thermo Fisher Scientific) packaging cell lines for virus production were cultured in 
DMEM high glucose supplemented with 10% fetal bovine serum and penicillin 
streptomycin. All cell lines have routinely been tested for mycoplasma contamination.  
 
Virus production 
Retroviral vectors were packaged using the Platinum-A (Cell BioLabs) cell line and 
lentiviral vectors were packaged using the 293FT cell line (Thermo Fisher Scientific) as 
previously described in Wagenblast et al. 2015
1
. 
 
Animal studies 
All mouse experiments were approved by the Cold Spring Harbor Animal Care and Use 
Committee. The maximal permitted tumour size of 20 mm in any direction was never 
exceeded. All mouse injections were carried out with 6 - 8-week-old female NOD-SCID-
Il2rg
−/−
 (NSG) mice (JAX). Balb/c mice were not used in this study as the different clonal 
cell lines have variable GFP levels due to the lentiviral barcode vector. Tail vein 
injections were carried out using 5 x 10
5
 mouse mammary tumour cells, which were re-
suspended in 100 ul of PBS and injected via tail vein. Orthotopic injections were 
performed using 1 x 10
5
 mouse mammary tumour cells or 5 x 10
5
 MDA-MB-231 cells. 
For this, cells were re-suspended in a 1:1 mix of PBS and growth factor reduced Matrigel 
(BD Biosciences). A volume of 20 ul was injected into the mammary gland number 4 for 
mouse mammary tumour cells and a volume of 40 ul was injected for MDA-MB-231 
cells. Primary tumour volume was measured using the formula V = 1/2(LxW
2
), where L 
is length and W is width of the primary tumour. For L-asparaginase studies, mice were 
administered 200 ul of 60 U of L-asparaginase (Abcam) 5 times per week through 
intraperitoneal injections. For L-asparagine adjusted diets, mice were given a control 
amino acid diet (0.6% asparagine), an asparagine deficient diet (0% asparagine) or an 
asparagine rich diet (4% asparagine). All diets were isonitrogenous and contained similar 
calorie densities. Sample size was chosen to give sufficient power for calling significance 
with standard statistical tests. Tumour and metastasis experiments were performed with 
10 animals per condition to account for the variability that is observed in such in vivo 
experiments. Animals were assigned to treatment groups through random cage selection. 
Mice were excluded from the analysis if the primary tumour engrafted into the 
peritoneum. All image quantifications were performed in a blinded manner. Source data 
is available for tumour volume measurements and lung metastases. 
 
Barcode analysis 
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The barcodes of the 4T1-E and 4T1-T cells were amplified and sequenced as previously 
described in Wagenblast et al. 2015
1
. 
 
In vivo shRNA lung screen and in vitro invasion screen 
shRNAs were predicted based on the Sherwood algorithm described in Knott et al. 2014
4
. 
Pools of ~50 shRNAs were packaged in Platinum-A cells. For each pool, 10 million 4T1-
T cells were infected at a multiplicity of infection (MOI) of 0.3. The infected cells were 
selected with 500 ug/ml hygromycin for 5 days and each pool was injected into 5 mice 
each via the tail vein. A pre-injection pool was collected at the time of injection to 
validate equal representation of each shRNA. After 7 days, mice were sacrificed and 
perfused with PBS to remove blood and non-extravasated cells from the lungs. Lungs 
were harvested and genomic DNA was isolated using phenol chloroform extraction. 
Genomic DNA of the pre-injection pools was isolated using the QIAamp DNA Blood 
Mini Kit (Qiagen).  
 
The in vitro invasion assays were carried out in parallel. Each pool was plated on two 6-
well BioCoat Matrigel invasion plates (Corning). 6 x 10
5 
cells were plated on top of each 
well in cell culture media without serum. Cells were allowed to invade through the 
matrigel into media containing 5% fetal bovine serum and 5% fetal calf serum for 24 h. 
Invaded cells were scraped off, washed with PBS and genomic DNA was isolated using 
the QIAamp DNA Blood Mini Kit.  
 
The shRNAs were amplified using a two-step PCR protocol previously described in 
Knott et al. 2014
4
 for next generation sequencing. 
 
First PCR forward primer 1: 5- CAG AAT CGT TGC CTG CAC ATC TTG GAA AC -3 
and reverse primer 1: 5- CTG CTA AAG CGC ATG CTC CAG ACT GC -3.  
 
Second PCR forward primer 2: 5- AAT GAT ACG GCG ACC ACC GAG ATC TAC 
ACT AGC CTG CGC ACG TAG TGA AGC CAC AGA TGT A -3 and reverse primer 2: 
5- CAA GCA GAA GAC GGC ATA CGA GAT NNN NNN GTG ACT GGA GTT 
CAG ACG TGT GCT CTT CCG ATC TCT GCT AAA GCG CAT GCT CCA GAC 
TGC -3. The reverse primer contained a barcode (NNNNNN) that enabled multiplexing. 
 
Analysis of screening data 
shRNA quantification was performed as described in ref 4. For each pool shRNA 
quantities in each sample were normalized by their sum, and log-fold changes were 
calculated using the initially infected cell population as a reference. Fold change values 
for each pool were then consolidated into a single table and an empirical Bayes 
moderated T-test was applied to identify depleted molecules. Genes with two or more 
depleted shRNAs were considered hits in each screen. 
 
Gene ontology enrichment analysis 
Gene Ontology enrichment analysis was performed using the GOrilla web portal. The 
Refseq identifiers of genes identified as over-expressed in 4T1-T cells, as compared to 
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4T1-E cells, were used as foreground and the entire Refseq gene list was used as 
background. 
 
Expression subtype and relapse analysis 
All clinical data analysis was performed using the University of North Carolina “855 
patient set”, which is available as published data at https://genome.unc.edu. All data was 
derived from an initial matrix that was arranged with patients on the horizontal axis and 
genes on the vertical axis. Initial normalization involved quantile normalization to ensure 
that the global expression profile of each patient was similar. Following this, each gene 
was z-score normalized across patients. For Extended Data Fig. 1a, the average 
expression level of each gene was calculated for each patient subtype. For Extended Data 
Fig. 1b, the average expression level of each gene was calculated for each gene for 
patients with and without relapse to each secondary site. For Extended Data Fig. 1d, the 
level of ASNS in each patient, stratified by subtype is plotted. For Extended Data Fig. 1e, 
each boxplot represents the level of ASNS in each patient with and without relapse to 
each secondary site. 
 
Individual in vitro invasion assay 
The in vitro invasive capacity of cells was measured using 6-well BioCoat Matrigel 
invasion plates. For parental 4T1 cells, 1 x 10
6 
cells were plated on individual wells, for 
4T1-T cells, 8 x 10
5 
cells were plated on individual wells and for MDA-MB-231 cells, 5 
x 10
5 
cells were used per individual well. Cells were re-suspended in media without 
serum and cells invaded into media with 5% fetal bovine serum and 5% fetal calf serum. 
For Fig. 3a and Extended Data Fig. 4b, 4T1 and MDA-MB-231 cells were cultured in 
media containing 100x concentration of the specified amino acid (relative to the 
concentration that is achieved by supplementing media with 1x NEAA) for 2 days or 3 
days, respectively, before starting the invasion assay. After 24 h, non-invaded cells were 
removed and the invasion wells were washed in PBS, fixed in 2% glutaaldehyde for 2 
min and stained with 0.5% crystal violet for 10 min. The wells were washed in distilled 
H2O, air-dried and scanned using the Odyssey infrared scanner. The signal was 
quantified using ImageJ (NIH). 
 
Competition and proliferation assay 
For the mCherry competition assay, shRNA-transduced mCherry-positive cells were 
admixed with untransduced cells. mCherry fluorescence was quantified on the LSR II 
flow cytometer (BD Biosciences). The proliferation assay was carried out using the 
CellTrace Violet Cell Proliferation Kit (Thermo Fisher Scientific). For Extended Data 
Fig. 4d, e, 4T1 and MDA-MB-231 cells were cultured in media containing 100x 
concentration of the specified amino acid (relative to the concentration that is achieved 
by supplementing media with 1x NEAA) for 2 days or 3 days, respectively, before 
starting the proliferation assay. Cells were stained with CellTrace violet and then 
trypsinized and re-suspended in media. After 24 h, cells were collected in order to 
quantify violet fluorescence intensity using the SH800 flow cytometer (Sony). 
 
Isolation of tumour and lung metastatic cells 
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Tumour and lung tissue were harvested, minced and digested into single cells as 
previously reported in Wagenblast et al. 2015
1
. Cells were either grown in 4T1 cell 
culture media containing 60 μM 6-thioguanine (6-TG) to deplete stromal cells or directly 
sorted based on mCherry expression using the FACSAria III cell sorter (BD 
Biosciences).  
 
RNAseq library preparation 
RNAseq libraries from cultured 4T1-T cells were prepared in duplicates as previously 
described in Wagenblast et al. 2015
1
. Each sample was sequenced on the Illumina HiSeq 
sequencer generating 76 nt single-end (SE) reads. 
 
RNAseq analysis 
Illumina sequencing reads were aligned to the mouse genome (mm10) using bowtie2 
with default parameters
17
. Genes were assigned a count using HTseq-count
18
. Differential 
expression analysis was performed using DESeq
19
.  
 
shRNA knock-down and cDNA overexpression studies  
Mouse and human cell lines were transduced with shRNA expressing retroviral or 
lentiviral constructs, respectively. After infection, 4T1-T cells were selected with 500 
ug/ml hygromycin for 5 days and MDA-MB-231 cells were selected with 2 ug/ml 
puromycin for 4 days. Cell lines infected with cDNA overexpressing retroviral constructs 
were selected with G418 for one week. The parental 4T1 cell line was selected with 600 
ug/ml G418 and MDA-MB-231 cells were selected with 1500 ug/ml G418. 
 
cDNA overexpression genes: 
mouse ASNS: NM_012055.1 
human ASNS: NM_001673.2 
 
shRNA knock-down sequences:  
mouse shAsns-1: 
TGCTGTTGACAGTGAGCGCCACTGCCAATAAGAAAGTATATAGTGAAGCCAC
AGATGTATATACTTTCTTATTGGCAGTGTTGCCTACTGCCTCGGA 
mouse shAsns-2: 
TGCTGTTGACAGTGAGCGCCACTATGAAGTTTTGGATTTATAGTGAAGCCACA
GATGTATAAATCCAAAACTTCATAGTGTTGCCTACTGCCTCGGA 
mouse shTgfb1-1:  
TGCTGTTGACAGTGAGCGCCAGTATATATATGTTCTTCAATAGTGAAGCCACA
GATGTATTGAAGAACATATATATACTGTTGCCTACTGCCTCGGA 
mouse shTgfb1-2: 
TGCTGTTGACAGTGAGCGAAGTATATATATGTTCTTCAAATAGTGAAGCCAC
AGATGTATTTGAAGAACATATATATACTGTGCCTACTGCCTCGGA 
human shASNS-1:  
TGCTGTTGACAGTGAGCGCCAGAAGCTAAAGGTCTTGTTATAGTGAAGCCAC
AGATGTATAACAAGACCTTTAGCTTCTGATGCCTACTGCCTCGGA 
human shASNS-2: 
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TGCTGTTGACAGTGAGCGCAGCAATGACAGAAGATGGATATAGTGAAGCCAC
AGATGTATATCCATCTTCTGTCATTGCTTTGCCTACTGCCTCGGA 
 
qRT-PCR 
Total RNA from cells was purified and DNAse treated using the RNeasy Mini Kit 
(Qiagen). For whole tissues, RNA was isolated using the TRIzol Plus RNA Purification 
Kit (Thermo Scientific). The tissue lysate was homogenized using a Dounce homogenizer 
and passed through a column homogenizer (Thermo Fisher Scientific) to reduce 
viscosity. RNA integrity (RNA Integrity score > 9) was measured on the Agilent 
Bioanalyzer (RNA nano kit). cDNA was synthesized using SuperScript III Reverse 
Transcriptase (Sigma). Quantitative PCR analysis was performed on the Eppendorf 
Mastercycler ep realplex. All signals were quantified using the ΔCt method and were 
normalized to the levels of Gapdh. For mCherry-positive flow cytometer sorted tumour 
and lung metastatic cells, cDNA was produced directly from lysed cells using the 
TaqMan Gene Expression Cells-to-Ct Kit (Thermo Fisher Scientific). Quantitative PCR 
analysis was performed on the CFX96 (Bio-Rad) using TaqMan primer/probe sets and all 
signals were quantified as described above. 
 
qRT-PCR primers  
mouse Asns (Exon 1 – 2): 
5'-CCT CTG CTC CAC CTT CTC T-3' 
5'-GAT CTT CAT CGC ACT CAG ACA-3' 
mouse Asns (Exon 6 – 7): 
5'-CCA AGT TCA GTATCC TCT CCA G-3' 
5'-CTT CAT GAT GCT CGCTTC CA-3' 
mouse Tgfb1 (Exon 1 – 2): 
5'-CCG AAT GTC TGA CGT ATT GAA GA-3' 
5'-GCG GAC TAC TAT GCT AAA GAG G-3' 
mouse Tgfb1 (Exon 3 – 4): 
5'-GTT ATC TTT GCT GTC ACA AGA GC-3' 
5'-CCC ACT GAT ACG CCT GAG-3' 
mouse Gapdh (Exon 2 – 3): 
5'-AAT GGT GAA GGT CGGTGT G-3' 
5'-GTG GAGTCA TACTGG AAC ATG TAG-3' 
human ASNS (Exon 8 – 9): 
5'-GAGTCA GAC CTT TGT TTA AAG CA-3' 
5'-GGA GTG CTT CAATGT AAC AAG AC-3' 
human ASNS (Exon 12 – 13): 
5'-CTG GAT GAA GTC ATATTT TCC TTG G-3' 
5'-CAG AGA AGATCA CCA CGCTAT C-3' 
human GAPDH (Exon 2 – 3): 
5'-ACA TCG CTC AGA CAC CAT G-3' 
5'-TGT AGT TGA GGT CAA TGA AGG G-3' 
 
TaqMan probes: 
Mouse Asns: Mm00803785_m1 
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Mouse E-cadherin (Cdh1): Mm01247357_m1 
Mouse Twist1: Mm00442036_m1 
Mouse Gapdh: Mm99999915_g1 
 
qPCR for circulating tumour cells (CTCs): 
CTCs were quantified as previously described in Wagenblast et al. 2015
1
. Genomic DNA 
was isolated from blood and CTC abundance was quantified using a qPCR assay against 
mCherry, which is expressed from the retroviral shRNA delivery vectors. 
 
mCherry probes and primers:  
primer 1: 5'-GACTACTTGAAGCTGTCCTTCC-3' 
primer 2: 5'-CGCAGCTTCACCTTGTAGAT-3' 
HEX probe: 5'-/56-FAM/TTCAAGTGG/ZEN/GAGCGCGTGATGAA/3IABkFQ//-3' 
Housekeeping probes and primers:  
primer 1: 5'-GACTTGTAACGGGCAGGCAGATTGTG-3' 
primer 2: 5'-GAGGTGTGGGTCACCTCGACATC-3' 
HEX probe: 5'-/5HEX/CCGTGTCGC/ZEN/TCTGAAGGGCAATAT/3IABkFQ/-3' 
 
Quantification of lung metastasis 
For each lung, five-micron sections were prepared and stained with a standard H&E 
protocol. Lung metastatic burden was determined by counting individual lung nodules on 
one section.  
 
E-cadherin and Twist1 analysis: 
For immunohistochemistry, primary tumours and lungs were processed as previously 
described in Wagenblast et al. 2015
1
. E-Cadherin (24E10) Rabbit mAb (3195, Cell 
Signaling) was utilized in a 1:400 dilution and Twist1 (Twist2C1a) Mouse mAb 
(ab50887, Abcam) was used in a 1:100 dilution. E-cadherin and Twist1 
diaminobenzidine-stained (DAB) and hematoxylin stainings were quantified using 
ImageJ (NIH). For this, images were color deconvoluted according to Ruifrok et al. 
2001
20
 and the percent area of E-cadherin and Twist1 positive staining was measured. 
 
Free amino acid quantification using HPLC 
Free amino acids were quantified in cultured cells and blood serum. For Extended Data 
Fig. 2e, 4T1-T cells were cultured under normal media conditions. For Extended Data 
Fig. 4a, c, 4T1 and MDA-MB-231 cells were cultured in media containing 100x 
concentration of the specified amino acid (relative to the concentration that is achieved 
by supplementing media with 1x NEAA) for 2 or 3 days, respectively. All cultured cells 
were washed in ice cold PBS, homogenized using a Dounce homogenizer and the lysate 
was subsequently filtered. Each biological sample was quantified in triplicates using High 
Performance Liquid Chromatography (HPLC) and a flourometric detector. For each 
replicate, nanomoles of each amino acid was measured. 
 
Proteomic profiling using isobaric tags for relative and absolute protein 
quantification (iTRAQ) 
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For each sample, raw peptide intensities were normalized by their sum. Peptides whose 
representation fell within the bottom quartile based on summed intensities across samples 
were not analyzed further. For the dataset represented in Fig. 4a and Extended Data Fig. 
7a-b, proteins were removed from subsequent analysis if fewer than 5 corresponding 
peptides were identified in any sample. Protein level differences between treatments were 
calculated based on the trimmed mean of corresponding peptide log-fold changes 
(trimming the top and bottom 25% for the experiment represented in Fig. 4a and 
Extended Data Fig. 7a-b, and the top and bottom 10% for the experiment represented in 
Fig. 4b). Relative protein abundances were calculated based on the trimmed mean of 
corresponding log transformed peptide intensities (trimming the top and bottom 25% and 
10% for the experiments represented in Fig. 4a and 4b, respectively). 
Metabolite profiling using liquid-chromatography tandem mass spectrometry (LC-
MS/MS) 
Organ tissue samples were placed in 2 ml lysing tubes prefilled with 1.4 mm ceramic 
beads for mammary glands or 2.8 mm ceramic beads for lungs and 1 ml of pre-chilled (-
80 °C) 80% methanol. Samples were homogenized with a Precellys24 homogenizer 
(Bertin Instruments) programmed with three 30 s cycles at 6500 Hz and 4 min pause 
times. At the end of each cycle, samples were snap-frozen in liquid nitrogen and placed 
on dry ice. Metabolite extraction of blood serum samples (50 ul) was performed using 
200 ul of 80% methanol at -80 °C. Following centrifugation for 10 min (13.2 kRPM, 4 
°C), supernatants were evaporated to dryness and stored at -80 °C until LC-MS/MS 
analysis. 
 
Dried-down extracts were re-suspended in 25 ul HPLC-grade water, and 1 ul was 
analysed using hydrophilic interaction chromatography (HILIC) coupled to tandem mass 
spectrometry analysis operated in the selected reaction monitoring mode (LC-SRM-MS). 
Analytical instrumentation consisted of a Nexera X2 (Shimadzu) liquid chromatography 
system with a XBridge BEH amide 2.1 x 100 mm, 2.5 μm column (Waters) and a 
QTRAP 6500 hybrid triple quadrupole / linear ion trap mass spectrometer (SCIEX) 
equipped with an electrospray ion source. Raw LC-SRM-MS data was acquired with 
Analyst 1.6.2 (SCIEX) and peak areas of LC-SRM-MS traces for each metabolite were 
integrated using the MultiQuant 1.1 software (SCIEX). Metabolite differences were 
analysed by normalizing samples to total peak area and comparing replicates for each 
group using one-way ANOVA with multiple comparisons.  
 
Amino acid compositional analysis 
For extended Data Fig. 7b, the amino acid representations of genes that showed the 
greatest decrease in their protein or RNA levels (bottom 25% log-fold change) were 
compared to those of the analysed gene set, using a rank-sum test. For the amino acid 
enrichment of protein- minus RNA-level expression changes, RNA- and protein-level 
log-fold changes were quantile normalized to the same distribution. RNA-level changes 
were then subtracted from protein-level changes. The amino acid representations of genes 
whose subsequent values fell within the lowest 25% were then compared to the analysed 
gene set using a rank-sum test, to identify amino acids whose abundance correlated with 
protein-level differences that were not explained by transcriptional changes. 
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For Extended Data Fig. 7c the same analysis was performed, this time comparing the 
proteins of genes that had been detected as up-regulated during EMT as compared to all 
other genes. For the murine amino acid enrichment, the EMT-up genes were mouse 
orthologues of the EMT-up human genes. 
 
For Extended Data Fig. 8, each organism harbouring a minimum of 10 genes that were 
orthologues of the pro-EMT human genes described in Extended Data Fig. 7c, were 
analysed. For each organism, the asparagine percentage of each protein was calculated. 
Then the asparagine enrichment level for each organism was determined by calculating 
the ratio of the median asparagine percentage of pro-EMT proteins vs. the remaining 
organism specific proteins. The statistical significance of enrichment was calculated as 
described for Extended Data Fig. 7c. 
 
Ribosome Profiling Analysis 
For analysis, quality trimming and linker removal was performed using cutadapt
22
. 
bowtie2 was used to remove reads that map to contaminating RNAs (e.g. rRNA and 
tRNA sequences)
17
. STAR was subsequently used to map reads of length 29-33 to the 
human transcriptome
23
. The offset was corrected for each read based on read length and 
12 and 15 nucleotides downstream were marked as P and A sites. For each gene, we then 
calculated the number of events at all positions and aggregated the counts for each codon 
and subsequently amino acid. 
 
Code Availability 
All custom code used during the current study will be made available by the 
corresponding author on reasonable request. 
 
Data Availability 
All raw and processed high-throughput sequencing data is available through the Gene 
Expression Omnibus (GEO) under the accession numbers GSE104968 and GSE107109. 
Source data is available for tumour volume measurements and lung metastases. All other 
datasets generated during and/or analysed during the current study will be made available 
by the corresponding author on reasonable request. 
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Figure Legends 
 
 
 
Figure 1:  Identification of metastatic drivers 
a, Relative proportions of 4T1-E and –T cells extracted from the lungs of NSG mice, into 
which mixtures of cells were introduced via tail vein at different concentrations. Each bar 
represents a sample or independent mouse. b, RNAi screening scheme to identify drivers 
of invasion in vitro and extravasation and colonization in vivo (n = 5 mice or n = 2 
matrigel 6-well invasion chambers per ~50 construct shRNA pool, gene-level hit calls 
with empirical bayes moderated t-test FDR < 0.05 and 0.1 for in vivo and in vitro screens, 
respectively). c, Overlap between genes identified in each arm of the RNAi screen 
depicted in b (hypergeometric test p-value < 0.01). 
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Figure 2: Validation of Asparagine Synthetase as a driver of invasion and metastasis 
a, Quantification of metastases in the lungs of mice that were intravenously injected with 
Asns-silenced or –expressing 4T1-T cells (n = 10 mice per cell line, edges of the box are 
the 25
th
 and 75
th 
percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 − 
w(q3 − q1), where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is also 
true for d, e and f, rank-sum test p-value < 0.001). b, Representative images of collection 
wells of the matrigel assay after Asns-silenced and –expressing cells were applied 24 h 
prior (n = 3 invasion chambers per cell line). c, Tumour volumes resulting from the 
orthotopic injection of the cells described in a (n = 10 mice per cell line). d, Relative 
abundance of CTCs in animals corresponding to the tumours described in c (n = 6 mice 
per cell line, rank-sum p-value < 0.05 for shAsns-2). e, Quantification of metastases in 
H&E stained lung sections, from mice described in d (rank-sum p-value < 0.0002). f, 
Average diameters of the metastases of each mouse described in e. See source data. 
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Figure 3: Extracellular asparagine availability drives invasion and metastasis 
a, Quantification of parental 4T1 cell invasion rates, as measured by the matrigel 
invasion assay, in culture media supplemented with the indicated non-essential amino 
acids (n = 5 invasion chambers, rank-sum p-value < 0.01). b, Representative H&E 
stained lung sections from animals that had been injected with Asns-silenced or –
expressing 4T1-T cells. Animals were administered L-asparaginase or PBS (n = 10 mice 
per condition). c, Quantification of lung metastases in animals that had been injected with 
Asns-silenced or –expressing 4T1-T cells. Animals were administered a diet with either 
0%, 0.6% or 4% asparagine content for the duration of the experiment (n = 10 mice per 
condition, rank-sum p-value < 0.05 for Asns-silenced vs. –expressing cells across all 
diets, for each cell line with 0% vs. 4% diets, for shRenila and shAsns-1 infected cells 
with 0% vs. 0.6% diet and for unsilenced cells with 0.6% vs. 4% diet). d, Mass-
spectrometric quantification of the asparagine levels in the mammary gland, blood serum 
and lungs of animals that were administered L-asparaginase or PBS (relative abundance 
normalized by total metabolite peak area, n > 8 tissue sections per condition, rank-sum p-
value < 0.005 for PBS vs. L-asparaginase across all tissues, rank-sum p-value < 0.05 for 
mammary gland vs. lung and rank-sum p-value < 0.0005 for serum vs. lung and serum 
vs. mammary gland). See source data. 
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Figure 4: Asparagine availability regulates epithelial-to-mesenchymal transition  
a, Relative protein abundances of EMT-up proteins in Asns-silenced and -expressing 
4T1-T cells (n = 3 replicates per cell line, edges of the box are the 25th and 75th 
percentiles, and error bars extend to the values q3 + w(q3 − q1) and q1 − w(q3 − q1), where 
w is 1.5 and q1 and q3 are the 25th and 75th percentiles, which is also true for b–d, rank-
sum P < 0.01). b, Relative protein abundances of EMT-up proteins in parental 4T1 cells 
when grown in normal and Asparagine-supplemented media (n = 3 replicates per cell 
line, rank-sum p-value < 0.05). c, Relative expression levels of EMT-up and EMT-down 
genes in lung metastases vs. primary tumours derived from orthotopic injection of 4T1-T 
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cells (n = 4 mice, rank-sum p-value < 5.0 x 10
-9 
for EMT-up genes). d, Relative 
expression levels of Twist1, Cdh1, EMT-up and EMT-down genes in cells that were 
isolated from tumours and lungs that were derived from Asns-silenced vs. Asns-
expressing 4T1-T cells (n = 4 replicates per condition, rank-sum p-value < 5.0 x 10
-11
 for 
EMT-down genes in the tumour and rank-sum p-value < 5.0 x 10
-8
 for EMT-up genes in 
the lung, Cdh1 was differentially expressed in the tumours and lungs and Twist1 was 
differentially expressed in tumours, DESeq FDR < 0.05). e, Representative images of 
IHC stainings for Twist1 and Cdh1 in orthotopic tumours that were derived from Asns-
silenced and –expressing 4T1-T cells. See source data. 
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Extended Data Figure Legends 
 
 
Extended Data Figure 1: Analysis of ASNS expression levels in patient data 
a, Expression level of genes identified as over-expressed in 4T1-T as compared to 4T1-E 
in the primary tumours of patients with different disease subtypes (edges of the box are 
the 25th and 75th percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 
− w(q3 − q1), where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is 
also true for b, d and e,  ANOVA p-value < 0.0001). b, Expression level of the same 
genes in disease free survivors and patients with relapse to the lung (rank-sum p-value < 
0.01) c, For each gene that was identified in the screen, a prognostic value was calculated 
 23 
using three different datasets. One consisted of gene expression measurements in three 
patient-matched Basal tumour and metastasis pairs (Patients A1, A7 and A11). Here 
genes were classified as correlated with progression if expression was higher in each of 
the metastases and negatively correlated if expression was higher in each of the 
primaries. The other two datasets consisted of primary tumour gene expression profiles 
with matched outcomes. For the UNC254 patient dataset, the site of relapse was not 
available and genes were deemed positively correlated with progression if they had 
significant relapse free survival hazard ratios > 1, and negatively correlated if these ratios 
were significant (cox p-value < 0.05) and < 1. As the UNC855 dataset also had site of 
relapse information, here both relapse free and lung relapse free survival (RFS and 
LRFS) hazard ratios were used to classify genes as positively or negatively correlated 
with progression based on the same criteria that were used for the UNC254 data. Shown 
are genes with human orthologues that were measured in the different datasets. d, 
Expression level of Asparagine Synthetase in the primary tumours of patients with 
different disease subtypes (ANOVA p-value < 0.0001). e, Expression level of Asparagine 
Synthetase in the primary tumours of patients with non-specific relapse and relapse to the 
lymph node, bone, brain, liver or lung in comparison to expression levels in patients 
without relapse to each corresponding site (rank-sum p-value < 0.005). f, Analysis of 
ASNS in 3 additional breast cancer patient sets (MDACC, METRABIC and TCGA). 
Shown are survival plots and relevant statistics (cox p-value < 0.01). g, Analysis of 
ASNS in the TCGA Pan Cancer expression data. Shown are survival plots and relevant 
statistics for the 10 non-breast solid-tumours represented in the dataset (cox p-value < 
0.05 for Colon, Squamous Head and Neck, Renal Clear Cell and Endometrial cancers). h, 
Analysis of ASNS across all tumours represented in the TCGA Pan Cancer dataset (cox 
p-value < 0.0001). 
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Extended Data Figure 2: Primary validation of Asns as a driver of invasion and 
metastasis 
a, Representative images of the lungs of mice that were intraveneously injected with 
Asns-silenced or –expressing 4T1-T cells as described in Fig. 2a. b, Quantification of 
matrigel invasion capacity for Asns-silenced and -expressing 4T1-T cells (n = 3 replicates 
per cell line). c, Quantification of mCherry-positive 4T1-T cells after roughly 50% of 
cells were infected with mCherry-expressing constructs harbouring shRNAs targeting 
Renilla Luciferase and Asparagine Synthetase. Cells were grown during the 24-hour 
period that the matrigel invasion assay described in Fig. 2b was being performed (n = 3 
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replicates per cell line). d, Violet cell-labelling intensity of Asns-silenced and –
expressing 4T1-T cells, relative to the initial population. Cells were grown during the 24-
hour period that the matrigel invasion assay described in Fig. 2b was being performed (n 
= 3 replicates per cell line). e, Free amino acid quantification by HPLC for each amino 
acid in Asns-expressing and –silenced cells. Shown are the log2-fold-changes in 
nanomoles per amino acid (n = 3 replicates per cell line. f, Quantification of mCherry-
positive 4T1-T cells after roughly 50% of cells were infected with mCherry-expressing 
constructs harbouring shRNAs targeting Renilla Luciferase and Asns. After infection 
cells were grown in L-asparagine or D-asparagine supplemented media and mCherry 
percentages were measured at 48 and 96 h (n = 3 replicates per cell line). g, 
Quantification of matrigel invasion for Asns-silenced and –expressing cells when assayed 
in media that has been supplemented with and without L-asparagine (n = 3 invasion 
chambers per cell line). 
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Extended Data Figure 3: Secondary validation of Asns as a driver of invasion and 
metastasis 
a, Volume measurements of tumours resulting from orthotopic injection of Asns-silenced 
and –expressing parental 4T1 cells (n = 10 mice per cell line, edges of the box are the 
25th and 75th percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 − 
w(q3 − q1), where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is 
also the case for b, c, d, e, f and g). b, Quantification of lung metastases corresponding to 
the tumours described in a (rank-sum p-value < 0.002). c, Volume measurements of 
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tumours resulting from orthotopic injection of parental 4T1 cells with basal (Empty) or 
enforced (Asns) expression of Asns (n = 10 mice per cell line). d, Quantification of lung 
metastases corresponding to the tumours described in c (rank-sum p-value < 5.0 x 10
-5
). 
e, Average diameters of the metastases of each mouse described in d (rank-sum p-value < 
0.001). f, Volume measurements for tumours resulting from orthotopic injection of 
MDA-MB-231 cells with basal (Empty) or enforced expression of ASNS (n = 10 mice 
per cell line). g, Quantification of lung metastases corresponding to the tumours 
described in f (rank-sum p-value < 0.005). h, Quantification of matrigel invasion for the 
MDA-MB-231 derived cell lines described in f (n = 3 invasion chambers per cell line). i, 
Representative images of the collection wells for the invasion assays described in h. See 
source data. 
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Extended Data Figure 4: Primary validation that extracellular asparagine 
availability impacts invasion and metastasis 
a, HPLC quantification of cellular free amino acid percentages for parental 4T1 cells 
when media is supplemented with each of the non-essential amino acids that is lacking in 
the DMEM culture media (n = 3 replicates per cell line). b, Quantification of MDA-MB-
231 matrigel invasion rates under the same conditions as was described in Fig. 3a (n = 5 
invasion chambers per condition, rank-sum p-value < 0.001). c, HPLC quantification of 
cellular free amino acid percentages for MDA-MB-231 cells when cultured in the media 
conditions described in a (n = 3 replicates per cell line). d, Violet cell-labelling intensity 
of parental 4T1 cells when they have been grown in asparagine-lacking and –
supplemented media for the same period that the matrigel invasion assay described in 
Fig. 3a was being performed (n = 3 replicates per cell line). e, Violet cell-labelling 
intensity of MDA-MB-231 cells when they have been grown in asparagine-lacking and –
supplemented media for the same period that the matrigel invasion assay described in b 
was being performed (n = 3 replicates per cell line). 
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Extended Data Figure 5: Secondary validation that extracellular asparagine 
availability impacts invasion and metastasis 
a, Tumour volumes resulting from the orthotopic injection of parental 4T1 cells. Half of 
the mice received L-asparaginase while the other half received an equivalent volume of 
PBS at the same injection rate (n = 10 mice per condition, edges of the box are the 25th 
and 75th percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 − w(q3 − 
q1), where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is also the 
case for b, d, e, f and g). b, Quantification of lung metastases detected in the animals 
described in a (rank-sum p-value < 0.001). c, Representative H&E stained lung sections 
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as described in b. d, Quantification of the lung metastases described in Fig. 3b, where 
Asns-silenced and –expressing 4T1-T cells were injected into mice. Half of the mice 
received L-asparaginase while the other half received an equivalent volume of PBS at the 
same injection rate (n=10 mice per condition, rank-sum p-value < 0.0005 for L-
asparaginase vs. control for each line and for Asns-silenced vs. –unsilenced cells in each 
drug condition). e, Tumour volumes corresponding to the lung metastases described in d 
(rank-sum p-value < 0.005 for Asns-silenced vs. –expressing cells in L-asparaginase 
treated mice). f, Lung metastases resulting from the orthotopic injection of ASNS-
silenced and –expressing MDA-MB-231 cells and subsequent treatment of the injected 
animals with L-asparaginase or PBS (n = 10 mice per cell line, rank-sum p-value < 0.05 
for ASNS-silenced vs. –expressing cells in both conditions and for silenced cells in 
treated vs. untreated mice). g, Tumour volumes corresponding to the mice described in f 
(rank-sum p-value < 0.05 for Asns-silenced vs. –expressing cells under both treatments 
and for PBS vs. L-asparaginase treated animals for each cell line). See source data. 
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Extended Data Figure 6: Tertiary validation that extracellular asparagine 
availability impacts invasion and metastasis 
a, Asparagine content in the serum free amino acid pool, for mice that have been fed 0%, 
0.6% or 4% asparagine diets (n = 5 mice per diet, edges of the box are the 25th and 75th 
percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 − w(q3 − q1), 
where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is also the case 
for b, d, e and h, rank-sum p-value < 0.05 between each diet). b, Volumes of orthotropic 
tumours corresponding to the lung metastases described in Fig. 3c, where Asns-silenced 
and –expressing 4T1-T cells were orthotopically injected into mice fed with 0%, 0.6% 
and 4% asparagine diets (n = 10 mice per condition). c, Representative images of the lung 
metastases described for Fig. 3c, which also correspond to the mice described in b. d, 
Volumes of tumours resulting from the orthotopic injection of parental 4T1 cells into 
mice fed with 0%, 0.6% or 4% asparagine diets (n = 10 mice per diet, rank-sum p-value < 
0.05 for mice receiving 0% vs. 0.6% and 0.6% vs. 4% diets). e, Quantification of 
metastases in the lungs of the animals described in d (rank-sum p-value < 0.05 between 
each diet). f, Representative images of H&E stained sections of the lungs described in e. 
g, Relative expression of Asns in the mammary gland, serum and lungs of mice that have 
been treated with L-asparaginase or PBS, as measured by qPCR with two primer pairs P1 
and P2 (n = 3 per condition). h, Transcripts Per Million (TPM) expression measurements 
for ASNS in human breast, lung and whole blood samples (n > 114 for each tissue, rank-
sum p-value < 2.8 x 10
-37
 blood vs. breast and lung). See source data. 
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Extended Data Figure 7: Primary validation that asparagine availability regulates 
EMT 
a, Protein-level changes between Asns-silenced and -expressing cells when genes are 
stratified by transcription-level changes (top and bottom 10% of genes based on log-fold 
change in Asns-silenced cells, Gene-up and -down, respectively) and asparagine content 
(top and bottom 10% of genes based on asparagine content, Asp-high and -low, 
respectively), edges of the box are the 25th and 75th percentiles and error bars extend to 
the values q3 + w(q3 − q1) and q1 − w(q3 − q1), where w is 1.5 and q1 and q3 are the 25th 
and 75th percentiles, which is also the case for d and e, rank-sum P < 5.0 × 10
-24
 for both 
individual variables, and rank-sum P < 0.005 for interacting variables). b, Amino acid 
enrichment analysis of downregulated genes (bottom 25% based on log-fold change) 
on the basis of RNA and protein levels in Asns-expressing versus -silenced 4T1-T 
cells. Negative correlations indicate the amino acid is depleted in the downregulated 
genes, while positive correlations indicate the amino acid is enriched. For protein minus 
RNA level expression changes, amino acids with positive correlations are enriched in 
proteins where depletion levels exceed what is predicted by corresponding RNA changes. 
Negative correlations indicate the amino acid is enriched in proteins where depletion 
levels are less than what is predicted by corresponding RNA changes (rank-sum 
P < 1.0 × 10
-5
 for asparagine in protein and protein–RNA). c, Amino acid enrichment in 
murine and human EMT-up proteins (rank-sum p-value < 0.01 for both human and 
mouse). d, Position 15 asparagine codon enrichment in ribosome protected fragments 
(RPFs) from PC-3 cells grown with and without L-asparaginase, when all genes or only 
EMT-up genes are analyzed (outliers were not plotted to improve interpretability and this 
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is also the case for e, rank-sum p-value < 0.05 for EMT-up vs. all genes in both untreated 
and L-asparaginase treated cells). e, Increase in Asparagine codon representation in 
RPFs, when PC-3 cells are grown in L-Asparaginase (relative to without), when all genes 
or EMT-up genes are analyzed (rank-sum p-value < 0.05). See source data. 
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Extended Data Figure 8: Conservation of asparagine enrichment in EMT promoting 
proteins 
Asparagine enrichment analysis of epithelial-to-mesenchymal promoting protein 
orthologues in the 126 species listed in the Orthologous MAtrix database that harbour at 
least 10 orthologues (rank-sum p-value < 1.0x10-13 for all species and rank-sum p-value 
< 9.0x10-9 for mammals vs. other species). 
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Extended Data Figure 9: Secondary validation that asparagine availability regulates 
EMT 
a, Transcription-level changes in EMT-up and –down genes that occur in response to 
Asns-silencing in 4T1-T cells (n = 2 replicates per condition, edges of the box are the 
25th and 75th percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 − 
w(q3 − q1), where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is 
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also the case for b, c, d, e, h and i, rank-sum p-value < 0.001 for EMT-up genes, DESeq 
FDR < 0.05 for Twist1 and Cdh1). b, Transcription-level changes in EMT-up and –down 
genes that occur in response to the media of parental 4T1 cells being supplemented with 
L-asparagine (n = 2 replicates per condition, rank-sum p-value < 0.005 for EMT-up 
genes). c, Gene expression changes in EMT-induced and EMT-repressed genes that result 
from ATF4 knockout in near haploid KBM-7 Chronic Myelogenous Leukemia (HAP-1 
cells, rank-sum p-value < 0.05). d, Gene expression changes in EMT-induced and EMT-
repressed genes, which result in the liver cells of homozygous ATF4 deleted mice when 
they have been treated with L-asparaginase (rank-sum p-value < 0.05 for EMT-down 
genes in WT+L-asp mice, and both EMT-up and –down genes in ATF4+L-asp mice). e, 
Volumes of tumours resulting from orthotopic injection of Tgf-ß-silenced and –
expressing 4T1-T cells (n = 10 mice per cell line). f, Percent Twist1 positive regions 
based on IHC staining of sections from tumours described in e (n = 5 tumour sections per 
cell line, rank-sum p-value < 0.01 for Asns-silenced vs. –expressing cells). g, Percent 
Cdh1 positive regions based on IHC staining of sections from tumours described in e (n = 
5 tumour sections per cell line, rank-sum p-value < 0.01 for Asns-silenced vs. –
expressing cells). h, Quantification of metastases resulting from the tumours described in 
e (rank-sum p-value < 0.05). i, Quantification of metastases resulting from intravenous 
injection of Tgf-ß-silenced and –expressing cells (10 mice per cell line, rank-sum p-value 
< 0.05). See source data. 
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Extended Data Figure 10: Tertiary validation that asparagine availability regulates 
EMT 
a, Representative H&E stained sections of the tumours described in Fig. 2c, where Asns-
silenced and –expressing 4T1-T cells were orthotopically injected into NSG mice. b, 
Images of cultured cells after they were isolated from the tumours and lungs of mice that 
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were injected orthotopically with Asns-silenced and –expressing 4T1-T cells. c, Relative 
Twist1 expression, as measured by qPCR, which were sorted from the tumours and lungs 
of mice that were injected orthotopically with Asns-silenced and –expressing 4T1-T cells 
(n = 3 tumours and lungs per cell line). d, Relative Cdh1 expression, as measured by 
qPCR, in the tumours and lungs described in c (n = 3 tumours and lungs per cell line). 
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Extended Data Figure 11: Quaternary validation that asparagine availability 
regulates EMT 
a, Representative images of IHC staining for Twist1 and Cdh1 on sections from lungs 
described in Fig. 4e, where mice were injected orthotopically with Asns-silenced and –
expressing 4T1-T cells. b, Quantification of all Twist1 stainings, described in Fig. 4e and 
a (n = 5 tumour sections and n > 5 lung metastases, edges of the box are the 25th and 
75th percentiles and error bars extend to the values q3 + w(q3 − q1) and q1 − w(q3 − q1), 
where w is 1.5 and q1 and q3 are the 25th and 75th percentiles and this is also the case 
for c, d, e, f and g, rank-sum p-value < 0.01 and < 0.05 for Asns-silenced vs. –expressing 
tumours and metastases, respectively). c, Quantification of all Cdh1 stainings, described 
in b (n = 5 tumour sections and n = 9 lung metastases, rank-sum p-value < 0.01 and < 
0.05 for Asns-silenced vs. –expressing tumours and metastases, respectively). d, 
Quantification of Twist1-positive regions in the tumours resulting from orthotopic 
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injection of Asns-expressing and –silenced 4T1-T cells into animals that are treated with 
PBS or L-asparaginase (n = 5 tumour sections per condition, rank-sum p-value < 0.01 for 
Asns-silenced vs. –unsilenced cells and rank-sum p-value < 0.05 for each cell line in 
treated vs. untreated mice). e, Quantification of Cdh1-positive regions in the tumours 
described in d (n = 5 tumour sections per condition, rank-sum p-value < 0.01 for Asns-
silenced vs. –unsilenced cells and rank-sum p-value < 0.05 for each cell line in treated vs. 
untreated mice). f, Quantification of Twist1-positive regions in tumours resulting from 
orthotopic injection of Asns-expressing and –silenced cells into mice fed a 0%, 0.6% or 
4% asparagine diet (n = 5 tumour sections per condition, rank-sum p-value < 0.01 
between Asns-silenced and –expressing cells and between diets). g, Quantification of 
Cdh1-positive regions in the tumours described in f (n = 5 tumour sections per condition, 
rank-sum p-value < 0.01 between Asns-silenced and –expressing cells and between 
diets).  
